This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Surface Oncology şirketinin toplam hissedar öz sermayesi $49.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $66.0M ve $16.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$56.26m
Eşitlik	US$49.18m
Toplam yükümlülükler	US$16.83m
Toplam varlıklar	US$66.01m

Son finansal sağlık güncellemeleri

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 23

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Jan 18

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Nov 11

Surface Oncology: Staying The Course

Oct 24

Surface Oncology: A Diverse, But Early Pipeline

Jul 13

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Jun 07

Surface Oncology EPS beats by $0.04, beats on revenue

May 05

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SURF 'nin kısa vadeli varlıkları ( $60.6M ) kısa vadeli yükümlülüklerini ( $16.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: SURF un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SURF borçsuzdur.

Borcun Azaltılması: SURF un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SURF şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: SURF un, serbest nakit akışı her yıl % 15 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company has been acquired

Surface Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Recent updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Price target decreased to US$5.25

Consensus forecasts updated

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Consensus revenue estimates increase by 46%

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Price target decreased to US$13.00

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Consensus forecasts updated

Price target decreased to US$14.75

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$21.0m

Investor sentiment deteriorated over the past week

Surface Oncology: A Diverse, But Early Pipeline

Chairman of the Board exercised options and sold US$862k worth of stock

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$28.1m

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology EPS beats by $0.04, beats on revenue

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Analysts lower revenue estimates to US$18.8m

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

New 90-day low: US$7.53

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

CEO, President & Director notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New 90-day high: US$10.70

Analysts update estimates

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program